Rituximab and reduced‐intensity chemotherapy in children and adolescents with mature B‐cell lymphoma: interim results for 231 patients enrolled in the second Russian‐Belorussian multicentre study B‐ NHL ‐2010M
| Autor: | Margarita B. Belogurova, Lebedev Vv, Alina Fedorova, N.V. Myakova, Natalia Ponomareva, Olga Aleinikova, Elena Samochatova, Natalia Grigor'eva, Nadezhda Smirnova, Egor Volchkov, Olga Nikonova, Guzel Sharapova, Alexey Maschan, Yulia Abugova, Larisa Fechina, Anastassia Shamardina, Anastassia Rudneva |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
medicine.medical_specialty Adolescent Republic of Belarus medicine.medical_treatment Gastroenterology Russia 03 medical and health sciences Antineoplastic Agents Immunological 0302 clinical medicine hemic and lymphatic diseases Internal medicine medicine Humans Prospective Studies Stage (cooking) Child Prospective cohort study Chemotherapy business.industry Remission Induction Reduced intensity Hematology medicine.disease Burkitt Lymphoma Combined Modality Therapy Lymphoma Treatment Outcome Child Preschool 030220 oncology & carcinogenesis Mature B-Cell Lymphoma Female Methotrexate Rituximab Immunotherapy Lymphoma Large B-Cell Diffuse business 030215 immunology medicine.drug |
| Zdroj: | British Journal of Haematology. 186:477-483 |
| ISSN: | 1365-2141 0007-1048 |
| Popis: | The value of adding rituximab to chemotherapy in children with aggressive B-cell non-Hodgkin lymphoma (B-NHL) is still insufficiently studied. We enrolled 231 patients [mean age 9 years old (range 2-17); male:female ratio 3·4:1] with Burkitt (BL, 179 patients, 76·7%), diffuse large B-cell (32 patients, 14%), primary mediastinal B-cell (14 patients, 6%), and other (6 patients, 2·6%) B-cell lymphomas in a prospective study of immuno-chemotherapy. Stages were I-II in 32% and III-IV in 68% of the patients. Four doses of 375 mg/m2 rituximab were added to the Berlin-Frankfurt-Munster-NHL-90-like chemotherapy, with methotrexate being reduced or omitted in the first 2 induction blocks. The complete remission rate was 100% in limited-stage and 91·4% in advanced-stage patients. Five advanced-stage patients (2·2%) died in induction and 1 patient with stage 2 B-NHL died in remission; 11 patients in the high-risk group progressed on therapy (3 non-BL are alive after salvage) and 5 relapsed. Sixteen patients (9·7%) with advanced stage disease proceeded to transplant. With a median follow-up of 46 months, 98·5 ± 1% of patients with limited disease and 88·1 ± 2% (88·1% in Risk Group 3; 82·6% in Risk Group 4) in advanced stages are alive. This study confirmed that combined immunochemotherapy for B-lymphomas is highly effective in children, despite reducing the intensity of the induction blocks. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text